EP Patent

EP3500257B1 — Kinase inhibitor compounds, compositions, and methods of treating cancer

Assigned to Icahn School of Medicine at Mount Sinai · Expires 2025-07-02 · 1y expired

What this patent protects

Patent listed against chembl-chembl1946170.

Drugs covered by this patent

chembl-chembl1946170 (REGORAFENIB)

Patent Metadata

Patent number: EP3500257B1
Jurisdiction: EP
Classification: —
Expires: 2025-07-02
Drug substance claim: No
Drug product claim: No
Assignee: Icahn School of Medicine at Mount Sinai
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.